Nektar Therapeutics (NKTR)
57.10
-2.28
(-3.84%)
USD |
NASDAQ |
Sep 25, 16:00
57.10
0.00 (0.00%)
After-Hours: 19:59
Nektar Therapeutics Research and Development Expense (Annual) : 117.07M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 117.07M |
| December 31, 2024 | 119.64M |
| December 31, 2023 | 111.29M |
| December 31, 2022 | 210.82M |
| December 31, 2021 | 390.45M |
| December 31, 2020 | 399.42M |
| December 31, 2019 | 426.42M |
| December 31, 2018 | 393.97M |
| December 31, 2017 | 260.09M |
| December 31, 2016 | 195.85M |
| December 31, 2015 | 176.27M |
| December 31, 2014 | 141.10M |
| December 31, 2013 | 171.17M |
| December 31, 2012 | 148.68M |
| December 31, 2011 | 126.77M |
| December 31, 2010 | 108.06M |
| Date | Value |
|---|---|
| December 31, 2009 | 95.11M |
| December 31, 2008 | 151.33M |
| December 31, 2007 | 147.78M |
| December 31, 2006 | 149.38M |
| December 31, 2005 | 151.66M |
| December 31, 2004 | 133.52M |
| December 31, 2003 | 131.53M |
| December 31, 2002 | 155.28M |
| December 31, 2001 | 139.65M |
| December 31, 2000 | 101.54M |
| December 31, 1999 | 64.08M |
| December 31, 1998 | 35.40M |
| December 31, 1997 | 23.64M |
| December 31, 1996 | 14.38M |
| December 31, 1995 | 9.041M |
| December 31, 1994 | 4.934M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Elite Pharmaceuticals, Inc. | 5.743M |
| Daré Bioscience, Inc. | 3.889M |
| Aclaris Therapeutics, Inc. | 52.64M |
| Eton Pharmaceuticals, Inc. | 7.765M |
| Journey Medical Corp. | 0.48M |